Showing results (221-230 of 295) with videos related to

Sort By:
Pageof 30
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsY Kanjanapan, D Day, M O Butler, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Current Oncology (Toronto, Ont.)|November 12, 2019
OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharingE R Malone, R R Saleh, C Yu, et al.
ESMO Open|June 13, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)V Gambardella, M K Accordino, P L Bedard, et al.
Journal of Gastrointestinal Oncology|January 13, 2023
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinomaKyaw L Aung, Elaine McWhirter, Stephen Welch, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 21, 2023
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)Sofia Genta, Katherine Lajkosz, Noelle R Yee, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant CancersKomal Jhaveri, Matthew T Chang, Dejan Juric, et al.
Scientific Reports|January 19, 2020
Latency and interval therapy affect the evolution in metastatic colorectal cancerHamid Nikbakht, Selin Jessa, Mahadeo A Sukhai, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Pageof 30